Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
Decision snapshot: ZNTL stock price vs SBRA: inconclusive Relative valuation is incomplete for this pair. Review the available filing metrics before drawing a conclusion.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at SBRA's multiple
Needs SBRA P/S.
Implied fair value · at ZNTL's multiple
Needs ZNTL P/S.
Metric by metric
Price unavailable
Where each company leads, and how wide the gap is.
Higher is better
Pricing power
Operating leverage
Lower is better
Not comparable
Lower leverage
Statements
Core statements aligned to each company's latest fiscal year.
SEC periods: ZNTL FY 2024 (ended Dec 31, 2024) · SBRA FY 2025 (ended Dec 31, 2025). Fiscal years are not aligned.
Trendline
Five fiscal years of revenue, earnings, and margins before underwriting a re-rating.
Price framework
Market cap plus debt, less cash.
Complete market value, debt and cash evidence is required for enterprise value.
Complete market value, debt and cash evidence is required for enterprise value.
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
Zentalis Pharmaceuticals, Inc. · implied price per share
Latest annual free cash flow must be positive to qualify the filing-backed baseline.
SABRA HEALTH CARE REIT, INC. · implied price per share
Five annual free-cash-flow observations are required for the filing-backed baseline.
Balance sheet health
Financial health checks to separate durable balance sheets from potential value traps.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Not enough data to score either balance sheet.
Debt / equity
Total debt against shareholders' equity
0.24x
0.90x
Net debt / EBITDA
Leverage against operating earnings
-0.29x
8.55x
Cash and equivalents
Liquid reserves on the balance sheet
$33.90M
$71.54M
Total debt
Interest-bearing obligations outstanding
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
Arcus Biosciences, Inc.
ZNTL vs RCUS
Repare Therapeutics Inc.
ZNTL vs RPTX
IDEAYA Biosciences, Inc.
ZNTL vs IDYA
Mersana Therapeutics, Inc.
ZNTL vs MRSN
EXELIXIS, INC.
ZNTL vs EXEL
WELLTOWER INC.
ZNTL vs WELL
MEDICAL PROPERTIES TRUST INC
ZNTL vs MPW
ALEXANDRIA REAL ESTATE EQUITIES, INC.
ZNTL vs ARE
NATIONAL HEALTH INVESTORS INC
ZNTL vs NHI
$82.57M
$2.53B
LLM-powered synthesis
An explanation of the financial evidence. Check its snapshot date against the figures above.
The deterministic comparison remains available. Sign in when you want an on-demand narrative synthesis of the same data.
